---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-041066"
form_type: "8-K"
ticker: "LGVN"
cik: "0001721484"
company_name: "Longeveron Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:57:19.940339+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Longeveron Q1 net loss $5.0M; HLHS trial 95% enrolled, BLA on track for 2026

## Summary
- Q1 2025 net loss $5.0M (up 23% YoY) on revenue $0.4M (down 30%); cash $14.3M, funding late into Q3 2025.
- HLHS pivotal trial ELPIS II ~95% enrolled, completion Q2 2025; BLA submission for full traditional approval anticipated in 2026.
- CLEAR MIND Alzheimer's Phase 2a results published in Nature Medicine; FDA agreed on pivotal Phase 2/3 trial design for BLA.
- Company plans to seek additional financing and partnerships for BLA readiness and Alzheimer's program.

## SEC filing metadata
- accession: 0001213900-25-041066
- form_type: 8-K
- ticker: LGVN
- cik: 0001721484
- company_name: Longeveron Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1721484/000121390025041066/0001213900-25-041066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1721484/000121390025041066/ea0241148-8k_longeveron.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-041066
- JSON: https://secwatch.observer/filing/0001213900-25-041066.json
- Plain text: https://secwatch.observer/filing/0001213900-25-041066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.